

Development and Validation of Stability Indicating UV Spectrophotometric Method for Simultaneous Estimation of Indacaterol and Mometasone Furoate in Pharmaceutical Dosage Form

Sanket M. Patil*, Sagar S. Kale, Ashwini R. Pawar, Pooja R. Yalmar.

Department of Pharmaceutical Chemistry
Sahyadri College of Pharmacy, Methwade, Sangola, Maharashtra, India
sanketpatil1999.sp@gmail.com

Abstract: A simple, accurate and precise stability indicating UV spectrophotometric method has been developed for simultaneous estimation of Indacaterol and Mometasone Furoate in pharmaceutical dosage form. The absorbance of Indacaterol and Mometasone Furoate was measured at two different wavelength 260 nm and 224 nm. It shows linear response between the concentration ranges 12-18 µg/ml and 25.6-38.4 µg/ml of regression coefficient r^2 being 0.9994 and 0.9994 of Indacaterol and Mometasone Furoate, respectively. A recovery study was carried out to confirm the methods accuracy. In the recovery study, the % RSD was less than 2. The % degradation by acidic, basic, oxidation, thermal and photolytic degradation of Indacaterol was found to be 5.39, 2.37, 3.46, 2.43 and 1.64%, while of Mometasone Furoate it was 2.37, 11.44, 1.18, 9.88 and 2.35%. The method for estimation of Indacaterol and Mometasone Furoate was found to be precise, specific, reproducible & economical, as per ICH guideline the results of analysis were validated and found to be satisfactory.

Keywords: Indacaterol, Mometasone Furoate, UV spectrophotometer, simultaneous estimation, Validation, Force degradation

I. INTRODUCTION

Indacaterol Acetate chemical name is (R)-5-(2-((5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one acetate. It is a longacting beta2-adrenergic agonist, which attributes to stimulate intracellular adenylyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. When inhaled, indacaterol acts locally in the lung as a bronchodilator, it has a rapid onset of action and a long duration of action.¹⁻³




Figure 1: Structure of Indacaterol Acetate

Mometasone furoate is (11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate. It is a synthetic corticosteroid with high affinity for glucocorticoid receptors and local anti-inflammatory properties.

Studies in asthmatic patients have demonstrated that inhaled mometasone furoate provides a favourable ratio of pulmonary to systemic activity. It is likely that much of the mechanism for the effects of mometasone furoate lies in its ability to inhibit the release of mediators of the inflammatory response.⁴⁻⁵




Figure 2: Structure of Mometasone Furoate

Literature review declares that no any UV spectrophotometric Method has been reported in order to estimate indacaterol and Mometasone Furoate respectively. In this research work a simple, precise and accurate UV method for simultaneous estimation of Indacaterol and Mometasone Furoate was developed and validated as per ICH guidelines.

II. MATERIALS AND METHODS

Instrumentation

A Shimadzu 1800 UV/VIS spectrophotometer with 1 cm matched quartz cells were used for all spectral measurements.⁶⁻⁷

For weighing, a calibrated weighing balance was used.

All the glassware's which was used were made up of Borosilicate and they were calibrated.

Chemicals and reagents –

Analytical pure sample of Indacaterol Acetate and Mometasone Furoate were received as gift sample from Anant Pharmaceuticals Pvt. Ltd. And Vamsi Labs Ltd. Solapur respectively. A Pharmaceutical dosage form used in this study was purchased from market labelled as INDAMET 320 contains Indacaterol Acetate Equivalent to Indacaterol of 150 µg and Mometasone Furoate of 320 µg.

The solvents used were Acetonitrile (AR grade) and distilled water to prepare mobile phase.

III. METHOD DEVELOPMENT

Selection of Wavelength

The sample was scanned from 190-400 nm with UV Spectrophotometer. The Wavelength selected for simultaneous analysis of Indacaterol chosen was 260 nm and for Mometasone Furoate was 224 nm. in Acetonitrile:Distilled Water (50:50 %v/v) mobile phase is used for good peaks, absorbance and better sensitivity. Shown in figure 3.




Figure 3: overlain spectra of Indacaterol Mometasone Furoate

Preparation of Mobile Phase –

1000 ml of mobile phase was prepared by mixing 500 ml of Acetonitrile and 500 ml of distilled water.(50:50 %v/v)

Preparation of Standard Stock Solution of Indacaterol –

Initially Prepare a Standard Stock Solution of Indacaterol by adding 7.5 mg of Indacaterol in 10 ml volumetric flask & add 5 ml diluent, mix for 2 minutes and make the volume to 10 ml with diluent. (Conc. of Indacaterol = 750 µg/ml).

Preparation of Standard Stock Solution of Momestason Furoate–

Then prepare a Standard Stock Solution of Momestason Furoate by adding 16 mg in 10 ml volumetric flask & add 5 ml diluent, mix for 2 minutes and make the volume to 10 ml with diluent.(Conc. of Momestason Furoate= 1600 µg/ml).

Then add 2.0 ml of Standard Stock Solution of Indacaterol & 2.0 ml Standard Stock Solution of Momestason Furoate in 100 ml volumetric flask and add 50 ml diluent and vortex and make up the volume with diluent. (Conc. of Indacaterol =15 µg/ml and Momestason Furoate = 32 µg/ml).

Simultaneous estimation of Indacaterol and Momestason Furoate –

Standard Solutions of different concentration of both drugs were prepared in mobile phase. Absorbance of Indacaterol (15 µg/ml) and Momestason Furoate (32 µg/ml) were recorded at two wavelength 260nm and 224 nm by using simultaneous equation method.⁸

$$C_x = \frac{A_1 a_{y2} - A_2 a_{y1}}{a_{x1} a_{y2} - a_{x2} a_{y1}}$$

$$C_y = \frac{A_1 a_{x2} - A_2 a_{x1}}{a_{y1} a_{x2} - a_{y2} a_{x1}}$$

Where,

A1= Absorbance of formulation at 260 nm

A2 = Absorbance of formulation at 224 nm

ax1 & ax2 = Absorptivity of Indacaterol at 260 nm & 224 nm

ay1 & ay2 = Absorptivity of at Momestason Furoate 260 nm & 224 nm

Cx = Concentration of Indacaterol

Cy = Concentration of Momestason Furoate

Sample Preparation –

10 Capsules content of brand INDAMET 320 were weighed and calculate average weight of 1 capsule content.

Powder weight equivalent to 150 µg Indacaterol and 320 µg of Momestason Furoate was weighed into 10 ml volumetric flask and add 5 ml diluent, sonicate for 5 minutes and make the volume to 10 ml with diluent. (Conc. of Indacaterol = 15 µg/ml and Momestason Furoate= 32 µg/ml).⁹⁻¹²

Table 1: Analysis of Marketed Formulation

Sr. no.	Indacaterol			Momestason Furoate		
	Absorbance	Amount recovered in µg/ml	% Recovery	Absorbance	Amount recovered in µg/ml	% Recovery
1	0.931	14.99	99.93	0.868	32.02	100.06
2	0.932	15.01	100.07	0.866	31.95	99.84
3	0.930	14.97	99.80	0.667	31.98	99.93
average	0.931	14.99	99.93	0.80	31.98	99.95
STDEV	0.001	0.02	0.133	0.115	0.035	0.109
RSD	0.107	0.133	0.133	14.42	0.109	0.109

IV. METHOD VALIDATION:

The developed method for simultaneous estimation of Indacaterol and Momestason Furoate was validated in terms of linearity, accuracy, precision, robustness, LOD and LOQ according to International Conference on Harmonization guidelines (ICH).¹³⁻¹⁴

Linearity and Range

Linearity was studied by plotting absorbance vs concentration and was found to be directly proportional. A series of standard solution of Indacaterol were prepared in the concentration range of 12 µg/ml to 18 µg/ml and for Momestason Furoate concentration range 25.6 µg/ml to 38.4 µg/ml is shown in table2 and table 3 respectively.

Linearity graph of Indacaterol and Momestason Furoate shown in Figure 4 and 5.

Indacaterol		
% Level	Conc. (ug/ml)	Absorbance at 260 nm
80	12	0.729
90	13.5	0.832
100	15	0.931
110	16.5	1.03
120	18	1.120

Table 2: Conc. Range and absorbance of Indacaterol

Momestason Furoate		
% Level	Conc. (ug/ml)	Absorbance at 224 nm
80	25.6	0.702
90	28.8	0.788
100	32	0.868
110	35.2	0.945
120	38.4	1.022

Table3: Conc. Range and absorbance of Momestason Furoate




Figure 4: Linearity graph of Indacaterol

DOI: 10.48175/IJARSCT-12401




Figure 5: Linearity graph of Momestason Furoate

Table 4: Linearity values of Indacaterol and Momestason Furoate

Parameter	Indacaterol	Momestason Furoate
Range	12-18 µg/ml	25.6-38.4 µg/ml
Slope	0.0653	0.0249
Intercept	0.0516	0.068
Corelation Coefficient	0.9994	0.9994

Precision/Repeatability –

Precision studies were carried in terms of Intra-day (at different time intervals on same day) and Inter-day (on three different days). It was performed as of three different concentrations of Indacaterol (12, 15 and 18 µg/ml) and Momestason Furoate (25.6, 32, 38.4 µg/ml). The %RSD was calculated shown in table.

conc. µg/ml	Absorbance			Mean Absorbance	SD	%RSD
	Trial 1	Trial 2	Trial 3			
12	0.729	0.728	0.730	0.729	0.001	0.137
15	0.931	0.930	0.932	0.931	0.001	0.107
18	1.120	1.121	1.122	1.121	0.001	0.089

Table 5: Intra-day precision study of Indacaterol

conc. µg/ml	Absorbance			Mean Absorbance	SD	%RSD
	Trial 1	Trial 2	Trial 3			
12	0.721	0.726	0.727	0.724	0.003	0.443
15	0.918	0.916	0.925	0.919	0.004	0.513
18	1.116	1.119	1.117	1.117	0.001	0.136

Table 6: Inter-day precision study of Indacaterol

conc. µg/ml	Absorbance			Mean Absorbance	SD	%RSD
	Trial 1	Trial 2	Trial 3			
25.6	0.706	0.702	0.701	0.703	0.002	0.376
32	0.865	0.868	0.867	0.866	0.001	0.176
38.4	1.024	1.022	1.027	1.024	0.002	0.245

Table 7: Intra-day precision study of Momestason Furoate

Table 8: Inter-day precision study of Mometasone Furoate

conc. µg/ml	Absorbance			Mean Absorbance	SD	%RSD
	Trial 1	Trial 2	Trial 3			
25.6	0.699	0.697	0.702	0.699	0.002	0.359
32	0.858	0.864	0.867	0.863	0.004	0.531
38.4	1.021	1.019	1.020	1.020	0.001	0.098

A single sample of each drug were prepared as described and 6 measurements of absorbance were made at 260 nm and 224 nm. % RSD was calculated for the obtained absorbances.

Table 9: Repeatability study of Indacaterol and Mometasone Furoate

	Indacaterol	Mometasone Furoate
	Absorbance at 259 nm	Absorbance at 224 nm
Rep 1	0.931	0.868
Rep 2	0.932	0.866
Rep 3	0.930	0.867
Rep 4	0.931	0.865
Rep 5	0.933	0.869
Rep 6	0.931	0.868
Average	0.931	0.867
STDEV	0.001032796	0.00147196
RSD	0.11	0.17

Accuracy

This parameter is performed to determine the closeness of the measured value to the true value which is expressed as % recovery. These studies were performed at three different levels (i.e. at 80%, 100% and 120%) and the % recovery of Indacaterol and Mometasone furoate was calculated and shown in table 10 and table 11 respectively.

STD wt. (mg)	Purity (%)	Potency (ug/ml)	STD Area
15	99.97	149.955	0.931

Table 10: Recovery study of indacaterol

Sample ID	Reps	Spiked Conc. (ug/ml)	Absorbance at 260 nm	Amt Recovered (ug/ml)	% Recovery	Average	STDEV	RSD
80%	Rep 1	12.00	0.729	11.74	97.84	97.75	0.154979	0.16
	Rep 2	12.00	0.729	11.74	97.84			
	Rep 3	12.00	0.727	11.71	97.58			
100%	Rep 1	15.00	0.931	14.99	99.96	99.96	0.107373	0.11
	Rep 2	15.00	0.932	15.01	100.07			
	Rep 3	15.00	0.930	14.97	99.86			
120%	Rep 1	17.99	1.120	18.03	100.21	99.95	0.54427	0.54
	Rep 2	17.99	1.110	17.87	99.32			
	Rep 3	17.99	1.121	18.05	100.30			

Table 11: Recovery study of Mometasone Furoate

STD wt. (mg)	Purity (%)	Potency (ug/ml)	STD Area
32	99.97	319.904	0.867

Sample ID	Reps	Spiked Conc. (ug/ml)	Absorbance at 224 nm	Amt Recovered (ug/ml)	% Recovery	Average	STDEV	RSD
80%	Rep 1	25.59	0.702	25.90	101.19	101.19	0.144148	0.14
	Rep 2	25.59	0.701	25.86	101.05			
	Rep 3	25.59	0.703	25.93	101.34			
100%	Rep 1	31.99	0.868	32.02	100.10	99.98	0.115318	0.12
	Rep 2	31.99	0.866	31.95	99.87			
	Rep 3	31.99	0.867	31.98	99.98			
120%	Rep 1	38.39	1.022	37.70	98.21	98.21	0.096098	0.10
	Rep 2	38.39	1.021	37.67	98.12			
	Rep 3	38.39	1.023	37.74	98.31			

Robustness

The analytical technique's robustness is a measure of its ability to remain unaffected by tiny but deliberate modifications in method of parameters, and it gives an indicator of its dependability in routine use. The Robustness was performed by changing the Diluent concentration by $\pm 2\%$.

Table 12: Robustness study of Indacaterol and Mometasone Furoate

Diluent Ratio			
Condition	Sample	Indacaterol	Mometasone Furoate
		Assay	Assay
52A-48W	DP 1	99.87	99.81
50A-50W	DP 2	99.91	99.84
48A-52W	DP 3	99.85	99.79
	Average	99.88	99.81
	SDEV	0.030	0.025
	RSD	0.030	0.025

LOD and LOQ –

LOD and LOQ calculated for both drugs using ANOVA technique.

$$LOD = \frac{3.3 \times \text{Std. Error of Intercept}}{\text{Coefficients of X Variable 1}}$$

$$LOQ = \frac{10 \times \text{Std. Error of Intercept}}{\text{Coefficients of X Variable 1}}$$

Sr no.	Name of drug	LOD in $\mu\text{g/ml}$	LOQ in $\mu\text{g/ml}$
1	Indacaterol	0.68	2.06
2	Mometasone Furoate	1.45	4.39

Table13: LOD and LOQ values of Indacaterol and Mometasone Furoate

V. FORCE DEGRADATION STUDY

To evaluate the stability condition of the developed UV-spectroscopic method samples were stressed in condition such as acid, base, oxidation, thermal and photolytic degradation. In all studies % degradation was calculated.¹⁵⁻¹⁶

Acid Degradation –

Acid degradation were carried out by weighing 15 mg Indacaterol and 32 mg Momestason Furoate in 10 ml Volumetric Flask. After addition of 1 ml 1 N HCL, the solution is stored at room temperature. Later the solution is diluted with diluent up to the mark. Further 1 ml of this solution is transferee in to 100 ml volumetric flask and diluted with diluent. This acid treated solution is scanned in UV range 190-400 nm.

Base Degradation -

Base degradation was carried out by weighing 15 mg Indacaterol and 32 mg Momestason Furoate in 10 ml Volumetric Flask. After addition of 1 ml 0.05 N NaOH, the solution is stored at room temperature. Later the solution is diluted with diluent up to the mark. Further 1 ml of this solution is transferee in to 100 ml volumetric flask and diluted with diluent. This acid treated solution is scanned in UV range 190-400 nm.

Oxidation –

Oxidative degradation was carried out by weighing 15 mg Indacaterol and 32 mg Momestason Furoate in 10 ml Volumetric Flask. After addition of 1 ml 30% hydrogen peroxide, the solution is stored at room temperature. Later the solution is diluted with diluent up to the mark. Further 1 ml of this solution is transferee in to 100 ml volumetric flask and diluted with diluent. This acid treated solution is scanned in UV range 190-400 nm.

Thermal Degradation –

Thermal degradation was carried out by weighing 15 mg Indacaterol and 32 mg Momestason Furoate in 10 ml Volumetric Flask. The solution is stored at 80°C for 8 hrs. Later the solution is diluted with diluent up to the mark. Further 1 ml of this solution is transferee in to 100 ml volumetric flask and diluted with diluent. This acid treated solution is scanned in UV range 190-400 nm.

Photolytic Degradation –

Photolytic degradation was carried out by weighing 15 mg Indacaterol and 32 mg Momestason Furoate in 10 ml Volumetric Flask. The solution is stored at 254 nm for 6 hrs. Later the solution is diluted with diluent up to the mark. Further 1 ml of this solution is transferee in to 100 ml volumetric flask and diluted with diluent. This acid treated solution is scanned in UV range 190-400 nm.

Table 14: Degradation study of Indacaterol and Momestason Furoate

Condition	Indacaterol		Momestason Furoate	
	% Recovery	% Deg.	% Recovery	% Deg.
Control	100	-	100	-
Acid	94.61	5.39	97.63	2.37
Base	97.63	2.37	88.56	11.44
Peroxide	96.54	3.46	98.82	1.18
Heat	97.57	2.43	90.12	9.88
UV	98.36	1.64	97.65	2.35

VI. RESULTS AND DISCUSSION

The proposed method is based on spectrophotometric simultaneous estimation of Indacaterol and Momestason Furoate. In this method Acetonitrile: distilled water(50:50 %v/v) is used as mobile phase. The Wavelength selected for simultaneous analysis of Indacaterol chosen was 260 nm and for Momestason Furoate was 224 nm.

Linearity-

Linear regression data for the calibration plots revealed good linear relationship between absorbance and concentration over the ranges 12 µg/ml to 18 µg/ml of Indacaterol and 25.6 µg/ml to 38.4 µg/ml of Momestason Furoate. The linear equation for the calibration plots were $y = 0.0653x - 0.0516$ and $y = 0.0249x + 0.068$ with Regression(R^2) being 0.9994 and 0.9994 for Indacaterol and Momestason Furoate, respectively.

Precision -

The precision of method was expressed as relative standard deviation (RSD%). The %RSD values for intra-day precision study and intra-day study listed in (Table 5,6, 7 and 8) were < 2 %, confirming that the method was sufficiently precise.

Accuracy-

When the method was used for accuracy and subsequent analysis of both the drugs from the pharmaceutical dosage form and spiked with 80, 120% of additional pure drug, the recovery was found to be 97.75 and 99.95% for Indacaterol and 101.19 and 98.21% for Mometasone Furoate.

LOD and LOQ -

The LOD and LOQ were calculated by equation. The LOD and LOQ values were 0.68 µg/ml and 2.06 µg/ml for Indacaterol and 1.45 µg/ml and 4.39 µg/ml for Mometasone Furoate.

Force degradation study –

The % degradation by acidic, basic, oxidation, thermal and photolytic degradation of Indacaterol was found to be 5.39, 2.37, 3.46, 2.43 and 1.64 %, while of Mometasone Furoate it was 2.37, 11.44, 1.18, 9.88 and 2.35%.

VII. CONCLUSION

The proposed method was developed for the Simultaneous estimation of Indacaterol and Mometasone Furoate was validated and found to be simple, accurate, precise and economical. The short spectral time makes this method suitable for processing of multiple samples in short time which indicates its competence for routine pharmaceutical analysis of Indacaterol and Mometasone Furoate in pharmaceutical dosage form. In addition, a forced degradation study can be used to determine the degradation pathways and degradation product of the APIs that could form during storage and facilitate formulation, development, manufacturing, and packaging.

ACKNOWLEDGEMENT

We are very thankful to Sahyadri College of Pharmacy, Methwade, Sangola, Maharashtra, for providing facilities and guidance to carry out the research work.

REFERENCES

- [1]. Clieff Battram et. al. (2006), In Vitro and In Vitro pharmacological characterization of Indacaterol, a novel inhaled beta 2 Adrenoreceptor agonist a 24-hr duration of action, Journal of pharmacology and experimental therapeutics, 317(2): 762-770.
- [2]. E. Naline et. al. (2007), Effect of Indacaterol, a novel long acting beta2 agonist, on isolated human bronchi, The European respiratory journal, 29(3): 575-581.
- [3]. Laurence J Brookman et. al. (2007), Efficacy and safety of single therapeutic and suprathreshold doses of indacaterol versus salmeterol and salbutamol in patients with asthma, Current medical research and opinion, 23(12): 3113-3122.
- [4]. Ricardo A Tan, Jonathan Corren (2008), Mometasone Furoate in the management of asthma: a review, Therapeutics and clinical risk management, 4(6): 1201-1208
- [5]. Eric Schenkel (2003), Features of Mometasone Furoate nasal spray and its utility in the management of allergic rhinitis, Expert opinion on pharmacotherapy.
- [6]. Skoog DA, West DM, and Holler FJ (2007), Fundamentals of Analytical Chemistry, 8th Edition; Thomson Brooks/Cole.
- [7]. Chatwal G.R. et al, (2008), Analytical chemistry, 1st ed. Himalaya Publication House.
- [8]. Beckett AH, Stenlake JB (2001) UV-visible Spectrophotometry, Practical Pharmaceutical Chemistry Part-II, 4th Edition; CBS Publishers and Distributors, New Delhi: 285-297.

- [9]. Sachin Ingale et.al. (2022) Formulation and Evaluation of Analytical Methods For determination of Indacaterol, International Journal for Research in Applied science and Engineering Technology, 10(6): 4676-4697.
- [10]. Nasr Mohamed A. et.al. (2018), Application of TLC densitometric and UV spectrophotometric techniques for simultaneous determination of Indacaterol and Glycopyrronium in inhalation capsules used for treatment of COPD, European journal of Biomedical and Pharmaceutical sciences, 5(5): 80-89.
- [11]. Heta D. Patel, Mehul M. Patel (2013), Development and Validation of UV Spectrophotometric Method for Simultaneous estimation of Terbinafine hydrochloride and Mometasone furoate in Combined Dosage Form, Asian journal of research in chemistry, 6(1): 29-34.
- [12]. Maulik N. Patel, Harsha D Jani, Priyanka S. Shah, Narmin A. Pirani (2016), Development and Validation of Analytical Method for Simultaneous Estimation of Mometasone Furoate and Fusidic Acid in Pharmaceutical Dosage Form, Journal of pharmaceutical sciences and bio scientific research, 6(3):247-253.
- [13]. ICH, Validation of Analytical Procedures: Text and Methodology. International Conference on Harmonization, IFPMA, Geneva 2005.
- [14]. Validation of Analytical Procedures: Text and Methodology Q2(R1), ICH Harmonized Tripartite Guideline.
- [15]. Blessy M. et. al. (2014), Development of Force Degradation and Stability indicating studies of drugs- A review, Journal of pharmaceutical analysis, 4(3): 159-165.
- [16]. Trivikram Rawat, I. P. Pandey, (2015), Forced degradation studies for Drug Substances and Drug Products- Scientific and Regulatory Considerations, Journal of Pharmaceutical Sciences and Research, 7(5): 238-241.